📰 Advanced Prostate News
Page 3 - Advanced Prostate News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Prostate. Real-time updates on events, politics, business and more.
February 24, 2022
/PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2021 Class of PCF Team Challenge Award recipients and a total of more than $9 million...
February 15, 2022
Investegate announcements from AstraZeneca PLC, Lynparza combo delays progression risk in prostate
February 1, 2022
Future of Vegan Fashion-Dr. Shields! Advanced Prostate Options-Dr. Krambeck! A Reason To Be-McCombs! Laura Shields, Ph.D., is a corporate responsibility officer
December 23, 2021
Learn about some of the most important clinical advances made at MSK in 2021.
December 14, 2021
/PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2021 Young Investigator Award recipients totaling nearly $6.5 million in...
November 2, 2021
In this interview, News-Medical talks to Dr. Simon Chowdhury and Laetitia Guilloux about the current state of prostate cancer, it's prevalence, treatment options and its future.
June 4, 2021
Investegate announcements from Arix Bioscience PLC, Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting
June 4, 2021
DJ Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting Arix Bioscience PLC (ARIX) Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO
June 4, 2021
DJ Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting Arix Bioscience PLC (ARIX) Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO
June 3, 2021
Novartis Pharma AG: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone 1 Significant improvem...